{
    "clinical_study": {
        "@rank": "151179", 
        "arm_group": {
            "arm_group_label": "Patient registry", 
            "description": "Patients with newly diagnosed malignant hematological diseases will be enrolled into this registry"
        }, 
        "brief_summary": {
            "textblock": "Objectives\uff1a\n\n        1. To assess the percentage of febrile neutropenia and suspected fungal-related febrile\n           episodes in patients receiving chemotherapy\n\n        2. To explore the percentage/distribution of infectious origins of febrile neutropenia\n\n        3. To explore the percentage/distribution of infectious pathogens of febrile neutropenia\n\n        4. To explore clinical outcomes of different infectious origins/pathogens in febrile\n           neutropenia episodes\n\n        5. To have a clear view of therapeutic actions in the management of hematological patients\n           with febrile neutropenia and suspected fungal-related febrile episodes"
        }, 
        "brief_title": "Registry of Febrile Neutropenia and Invasive Fungal Infections", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hematological Disease", 
            "Febrile Neutropenia", 
            "Fungal Infections"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Fever", 
                "Hematologic Diseases", 
                "Mycoses", 
                "Neutropenia"
            ]
        }, 
        "detailed_description": {
            "textblock": "Objectives\uff1a\n\n        1. To assess the percentage of febrile neutropenia and suspected fungal-related febrile\n           episodes in patients receiving chemotherapy\n\n        2. To explore the percentage/distribution of infectious origins of febrile neutropenia\n\n        3. To explore the percentage/distribution of infectious pathogens of febrile neutropenia\n\n        4. To explore clinical outcomes of different infectious origins/pathogens in febrile\n           neutropenia episodes\n\n        5. To have a clear view of therapeutic actions in the management of hematological patients\n           with febrile neutropenia and suspected fungal-related febrile episodes\n\n      Study Design\uff1a\n\n        -  This is a single institute, prospective, non-interventional registry for monitoring\n           events of febrile neutropenia in hematological patients\n\n        -  Patients with newly diagnosed malignant hematological diseases will be enrolled into\n           this registry\n\n      Study Procedures\uff1a Data collection will include patients' basic information, underlying\n      disease, baseline blood chemistry and blood cell counts, antifungal prophylaxis, C/T\n      regimens, neutrophils and other blood cells, fever diagnosis and infectious sites work-up,\n      clinical response, microbiology (including bacteria and fungus culture), renal and liver\n      function, clinical diagnosis, work-up and intensive procedures and results, antifungal and\n      antibacterial agents (including dosage, duration, and route), other drugs used (including\n      antivirals, antineoplastics, corticosteroids, immunomodulators), clinical significant\n      changes\n\n      Sample Size Calculation and Statistical Analysis\uff1a Approximately 100 febrile neutropenia\n      episodes in 500 chemotherapy cycles will be collected. This is an observational and\n      exploratory study without hypothesis tests. Study subjects will be collected and monitored\n      under normal clinical practice, and the sample size will be limited due to the hospital\n      scale and disease characteristic (the sample size calculation is inapplicable here). All\n      evaluations will be shown by exploratory and descriptive data analysis. The number of cases\n      for each investigative definition, the corresponding percentage and the 95% confidence\n      interval will be described."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with new diagnosed hematological diseases (acute and chronic myeloid and\n             lymphoid leukemia, multiple myeloma, non-Hodgkin's and Hodgkin's lymphoma,\n             myelodysplastic syndromes)\n\n          -  Patients who are receiving chemotherapy and have ongoing febrile episodes\n\n        Exclusion Criteria:\n\n          -  None"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with newly diagnosed malignant hematological diseases"
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01684189", 
            "org_study_id": "MISP38887"
        }, 
        "intervention": {
            "arm_group_label": "Patient registry", 
            "description": "Patient registry without study intervention", 
            "intervention_name": "Patient registry", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 11, 2012", 
        "location": {
            "contact": {
                "email": "wang9595@ms32.hinet.net", 
                "last_name": "Ming-Chung Wang, M.D.", 
                "phone": "+886-7-7317123", 
                "phone_ext": "3266"
            }, 
            "facility": {
                "address": {
                    "city": "Kaohsiung", 
                    "country": "Taiwan", 
                    "zip": "833"
                }, 
                "name": "Kaohsiung Chang Gung Memorial Hospital"
            }, 
            "investigator": {
                "last_name": "Ming-Chung Wang, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Non-interventional Prospective Registry to Monitor the Events of Febrile Neutropenia and Invasive Fungal Infections and the Diagnostic and Therapeutic Management in Patients With Malignant Hematologic Diseases After Chemotherapy", 
        "overall_contact": {
            "email": "wang9595@ms32.hinet.net", 
            "last_name": "Ming-Chung Wang, M.D.", 
            "phone": "+886-7-7317123", 
            "phone_ext": "3266"
        }, 
        "overall_official": {
            "affiliation": "Kaohsiung Chang Gung Memorial Hospital", 
            "last_name": "Ming-Chung Wang, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Taiwan : Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01684189"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Chang Gung Memorial Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chang Gung Memorial Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2011", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "November 2011"
    }
}